ulcerative colitis
Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis
Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
Pfizer teams up with Google-backed 23andMe
August 13, 2014Research and Development, Sales and Marketing 23andME, Crohn’s disease, Pfizer, google, ulcerative colitis
Pfizer and genetics testing firm 23andMe have come together in a research pact aimed at finding the genetic cause of …
AbbVie highlights treatment adherence
June 12, 2014Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis
Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …
Humira gains European licence for ulcerative colitis
April 11, 2012Sales and Marketing Humira, ulcerative colitis
Abbott’s Humira has gained European approval to treat ulcerative colitis, adding to its six existing licences. It can now …
Ulcerative colitis market set to double by 2018
February 12, 2010Sales and Marketing Humira, Simponi, TNF, ulcerative colitis
The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …
Latest content
